Iovance Biotherapeutics (IOVA) Other Non-Current Assets (2011 - 2026)

Iovance Biotherapeutics (IOVA) has reported Other Non-Current Assets for 12 consecutive years, with $8.3 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Other Non-Current Assets rose 1846.24% year-over-year to $8.3 million; the TTM figure through Mar 2026 stood at $8.3 million (up 1846.24% YoY), while the FY2025 annual figure was $6.0 million, down 5.96% from the prior year.
• Other Non-Current Assets grew to $8.3 million in Q1 2026 per IOVA's latest filing, from $6.0 million in the prior quarter.
• Across five years, Other Non-Current Assets topped out at $66.4 million in Q2 2023 and bottomed at $189000.0 in Q4 2022.
• Historically, Other Non-Current Assets has averaged $9.0 million across 5 years, with a median of $6.4 million in 2024.
• Annual changes were most pronounced in 2022 — Other Non-Current Assets tumbled 96.89% — and 2024, when it soared 2255.19%.
• Iovance Biotherapeutics' Other Non-Current Assets stood at $189000.0 in 2022, then jumped by 42.86% to $270000.0 in 2023, then jumped by 2255.19% to $6.4 million in 2024, then fell by 5.96% to $6.0 million in 2025, then soared by 38.65% to $8.3 million in 2026.
• Business Quant data shows IOVA's Other Non-Current Assets at $8.3 million in Q1 2026, $6.0 million in Q4 2025, and $9.3 million in Q3 2025.